AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
- Olympus CEO Stefan Kaufmann resigned after an internal probe into allegations of illegal drug purchases.
- Kaufmann, the second non-Japanese CEO of the company, served since April 2023.
- Chairman Yasuo Takeuchi will act as interim CEO while the search for Kaufmann's successor begins.
Japanese medical technology company Olympus Corporation has announced the resignation of its CEO, Stefan Kaufmann, following an internal investigation into allegations of illegal drug purchases. The German executive, who had held the position since April 2023, stepped down after the company's board determined that his actions breached the company’s global code of conduct.
The company revealed in a statement that it had acted swiftly upon receiving information about Kaufmann's alleged misconduct. "Upon receiving an allegation that Mr. Stefan Kaufmann had purchased illegal drugs, Olympus, in consultation with outside legal counsel, immediately investigated the facts, made a report to the investigative authorities, and cooperated fully with their investigation," the company said.
The Olympus board reviewed the findings of the investigation and unanimously concluded that Kaufmann’s actions were incompatible with the company’s standards. Following this, Kaufmann offered his resignation, which the board accepted. Details regarding the nature of the allegations or how the matter came to light have not been disclosed by the company.
Leadership Shake-Up Amid Controversy
Kaufmann’s departure marks the second time a foreign executive at Olympus has faced a dramatic exit. He was the second non-Japanese person to serve as the company's chief executive, having taken over in April 2023. Kaufmann joined Olympus’ European operations in 2003 and rose through the ranks, eventually taking the helm at the global level.
His predecessor as the company’s first non-Japanese CEO, Michael Woodford, faced a similarly abrupt departure in 2011. Woodford was dismissed just weeks into his tenure after investigating potential financial irregularities within the company. The incidents involving both foreign leaders underscore the company's history of executive turmoil.
Interim Leadership and Search for a New CEO
Following Kaufmann’s resignation, Olympus has appointed Chairman Yasuo Takeuchi to serve as the interim CEO. The company indicated that the search for a permanent successor is underway, though no timeline has been provided for when a new leader will be named.
The sudden leadership change comes at a critical time for Olympus, which has been undergoing strategic shifts to focus on its core medical technology and life sciences businesses. Under Kaufmann's brief leadership, the company aimed to accelerate growth through innovations in medical equipment and imaging solutions.
With Takeuchi now steering the company on a temporary basis, the board will need to find a successor who can maintain momentum while addressing any potential reputational impacts from the scandal. As Olympus navigates the leadership transition, the company will continue its strategic initiatives under Takeuchi's interim guidance.
The resignation of Kaufmann adds to a complex chapter in Olympus’ history, following high-profile leadership controversies in the past. The company’s swift response in addressing the allegations indicates a commitment to upholding ethical standards, even as it faces the task of stabilizing its executive ranks once again.
